Overview of antibody therapy in B-cell non-Hodgkin's lymphoma

Clinical Lymphoma

Volumn 4, Issue SUPPL. 1, 2003, Pages

  Wannesson, Luciano ^a   Ghielmini, Michele ^a  

^a OSPEDALE SAN GIOVANNI   (Switzerland)

Author keywords

Indolent lymphoma; Large cell lymphoma; Macroglobulinemia; Mantle cell lymphoma; Rituximab

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; APOLIZUMAB; CARBOPLATIN; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; EPRATUZUMAB; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IBRITUMOMAB TIUXETAN; IFOSFAMIDE; IMMUNOMODULATING AGENT; INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; LEUKOCYTE ANTIBODY; MELPHALAN; MEPREDNISONE; MITOXANTRONE; PREDNISONE; RITUXIMAB; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

APLASIA; ARTICLE; B CELL LYMPHOMA; BIOENGINEERING; BONE MARROW SUPPRESSION; CANCER CLASSIFICATION; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; FOLLICULAR LYMPHOMA; HUMAN; IN VIVO STUDY; LARGE CELL LYMPHOMA; MANTLE CELL LYMPHOMA; MONOTHERAPY; NONHODGKIN LYMPHOMA; SIDE EFFECT; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA;

EID: 0142029059     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2003.s.002     Document Type: Article

References (61)

1. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83:435-445.
2. Demidem A, Lam T, Alas S, et al. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997; 12:177-186.
3. Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol 2002; 29:2-9.
4. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20:2453-2463.
5. Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001; 19:3918-3928.
6. Kreitman RJ, Wilson WH, Bergeron K, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 2001; 345:241-247.
7. Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001; 19:3244-3254.
8. Nadler LM, Stashenko P, Hardy R, et al. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res 1980; 40:3147-3154.
9. Nadler LM, Ritz J, Griffin JD, et al. Diagnosis and treatment of human leukemias and lymphomas utilizing monoclonal antibodies. Prog Hematol 1981; 12:187-225.
10. Brown SL, Miller RA, Levy R. Antiidiotype antibody therapy of B-cell lymphoma. Semin Oncol 1989; 16:199-210.
11. Davis TA, Maloney DG, Czerwinski DK, et al. Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone. Blood 1998; 92:1184-1190.
12. Osterborg A, Dyer MJ, Bunjes D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 1997; 15:1567-1574.
13. Lundin J, Osterborg A, Brittinger G, et al. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. J Clin Oncol 1998; 16:3257-3263.
14. Uppenkamp M, Engert A, Diehl V, et al. Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high- and low-grade non-Hodgkin's lymphomas: a multicenter phase I/II study. Ann Hematol 2002; 81:26-32.
15. Link B, Kahl B, Czuczman M, et al. A phase II study of Remitogen™ (Hu1D10), a humanized monoclonal antibody in patients with relapsed or refractory follicular, small lymphocity, or marginal zone/MALT B-cell lymphoma. Blood 2001; 98(suppl):606a (Abstract #2540).
16. Leonard J, Coleman M, Ketas J, et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol 2003; 21:3051-3059.
17. Czuczman M, Witzig T, Younes A, et al. IDEC-114, an Anti-CD80 Monoclonal Antibody for Relapsed or Refractory, Follicular NHL: Phase I/II Study of Safety, Efficacy, and Pharmacokinetics. Blood 2002; 100(suppl):163a (Abstract #610).
18. Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994; 84:2457-2466.
19. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997; 15:3266-3274.
20. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16:2825-2833.
21. Berinstein NL, Grillo-Lopez AJ, White CA, et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998; 9:995-1001.
22. Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001; 97:101-106.
23. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998; 92:1927-1932.
24. Foran JM, Rohatiner AZ, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000; 18:317-324.
25. Conconi A, Thieblemont C, Martinelli G, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood 2003. In press.
26. Hainsworth JD, Burris HA III Morrissey LH, et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 2000; 95:3052-3056.
27. Davis TA, Grillo-Lopez AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000; 18:3135-3143.
28. Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001; 19:2153-2164.
29. O'Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001; 19:2165-2170.
30. Piro LD, White CA, Grillo-Lopez AJ, et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1999; 10:655-661.
31. Dimopoulos MA, Zervas C, Zomas A, et al. Extended rituximab therapy for previously untreated patients with Waldenstrom's macroglobulinemia. Clin Lymphoma 2002; 3:163-166.
32. Treon S, Emmanouilides C, Kimby E, et al. Extended rituximab therapy is highly active and facilitates hematological recovery in patients with lymphoplasmacytic lymphoma (Waldenstrom's macroglobulinemia, WM). Proc Am Soc Clin Oncol 2002; 21(suppl):268a (Abstract #1068).
33. Hainsworth JD, Litchy S, Burris HA III et al. Rituximab, as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 2002; 20:4261-4267.
34. Ghielmini M, Hsu Schmitz S, Cogliatti S, et al. Prolonged Treatment with rituximab significantly improves event free survival and duration of response in patients with follicular lymphoma: a randomised SAKK trial. Blood 2002; 100(suppl):161a (Abstract #604).
35. Gordon L, Grow W, Braylan R, et al. Phase II trial of individualized pharmacokinetic dosing of rituximab maintenance for patients with CD20 positive lymphoproliferative disorders. Blood 2002; 100(suppl):362a (Abstract #1400).
36. Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17:268-276.
37. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:235-242.
38. Kewalramani T, Zelenetz AD, Bertino J, et al. Rituximab significatly increases the complete response rate in patients with relapsed or primary refractory DLBCL receiving ICE as second-line therapy (SLT). Blood 2001; 98(suppl):346a (Abstract #1459).
39. McLaughlin P, Hagemeister FB, Rodriguez MA, et al. Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. Semin Oncol 2000; 27:37-41.
40. Hiddemann W, Forstpointner R, Fiedler F, et al. Combined immunochemotherapy (R-FMC) is superior to a fludarabine-containing chemotherapy (FMC) alone in recurrent follicular and mantle cell lymphoma-results of a prospective randomized comparison of the German low-grade lymphoma study group. Ann Oncol 2002; 13(suppl 2):57 (Abstract #186).
41. Magni M, Di Nicola M, Devizzi L, et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood 2000; 96:864-869.
42. Flinn I, Jones R, Goodrich A, et al. Rituximab during autologous stem-cell transplantation for lymphoma produces lymphoma free grafts in most patients by PCR and clonogenic assays. Blood 2001; 98(suppl):676a (Abstract #2832).
43. Buckstein R, Imrie K, Spaner D, et al. Autologous stemm cell transplants combined with rituximab for relapsed follicular lymphoma achieve prolonged clinical and molecular remissions. Blood 2001; 98(suppl):680a (Abstract #2846).
44. Cortelazzo S, Rambaldi A, Rossi A, et al. High-dose sequential (HDS) chemotherapy with high-dose ARA-C and rituximab prolongs the survival of patients with resistant/relapsed B-cell non-Hodgkin's lymphoma. Blood 2002; 100(suppl):646a (Abstract #2542).
45. Faderl S, Thomas DA, O'Brien S, et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 2003; 101:3413-3415.
46. Sacchi S, Federico M, Vitolo U, et al. Clinical activity and safety of combination immunotherapy with IFN-alpha 2a and rituximab in patients with relapsed low grade non-Hodgkin's lymphoma. Haematologica 2001; 86:951-958.
47. Ansell SM, Witzig TE, Kurtin PJ, et al. Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Blood 2002; 99:67-74.
48. van der Kolk LE, de Haas M, Grillo-Lopez AJ, et al. Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils. Leukemia 2002; 16:693-699.
49. Friedberg JW, Neuberg D, Gribben JG, et al. Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. Br J Haematol 2002; 117:828-834.
50. Kimby E, Geisler C, Hagberg H, et al. Rituximab (MabThera®) as single agent and in combination with interferon-alfa-2a as treatment of untreated adn first relapse follicular or other low grade lymphomas. A randomized pase II study. Blood 2000; 96(suppl):577a (Abstract #2479).
51. Foran JM, Gupta RK, Cunningham D, et al. A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. Br J Haematol 2000; 109:81-88.
52. Czuczman M, Fallon A, Mohr A, et al. Phase II study of rituximab plus fludarabine in patients (pts.) with low-grade lymphoma. Blood 2001; 98(suppl):601a (Abstract #2518).
53. Hiddemann W, Forstpointner R, Mohr A, et al. Combined immunotherapy (R-FCM) is superior to a fludarabine-containing chemotherapy (FCM) alone in recurrent indolent lyphoma - results of a prospective randomized caompairson of the German Low Grade Lymphoma Study Group. Onkologie 2001; 24:90A.
54. Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003; 101:4279-4284.
55. Gianni AM, Magni M, Martelli M, et al. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood 2003; 102:749-755.
56. Forstpointner R, Hanel A, Repp R, et al. [Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas-results of a prospective randomized study of the German Low-Grade Lymphoma Study Group]. Dtsch Med Wochenschr 2002; 127:2253-2258.
57. Romaguera J, Cabanillas F, Dang N, et al. Mantle cell lymphoma (MCL)-high rates of complete remission (CR) and prolonged failure free survival (FFS) with rituxan-HyperCVAD (R-HCVAD) without stem cell transplant (SCT). Blood 2001; 98(suppl):726a (Abstract #3030).
58. Howard OM, Gribben JG, Neuberg DS, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002; 20:1288-1294.
59. Thomas D, Cortes J, Giles F, et al. Rituximab and hyper-CVAD for adult Burkitt's (BL) or Burkitt's-like (BLL) leukemia or lymphoma. Blood 2002; 100(suppl):763a (Abstract #3022).
60. Witzig T, Flinn I, Gordon L, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002; 20:3264-3269.
61. Horning S, Lucas J, Younes A, et al. Iodine-131 tositumomab for non-Hodgkin's lyphoma patients who progressed after treatment with rituximab: results of a multicenter phase II study. Blood 2000; 96(suppl):508a (Abstract #2184).